{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:35:41Z","timestamp":1793860541220,"version":"4.6.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent developments in the management of chronic lymphocytic leukemia (CLL) have moved the standard of care away from chemoimmunotherapy to targeted agents such as oral kinase inhibitors or BCL-2 antagonists, alone or in combination with anti-CD20 antibodies. Two different treatment approaches have evolved: continuous, indefinite treatment and, more recently, fixed-duration combination treatment. With venetoclax-based treatment, there is a requirement to follow the established guidelines for close monitoring during initiation and ramp up, to reduce the risk of tumor lysis syndrome. The patient\u2019s risk should be assessed before the initiation of venetoclax. Appropriate management strategies should be used, including uricosuric agents, hydration, and routine laboratory monitoring, per guidelines. With early identification, immediate management, and dose adjustments, we suggest that tumor lysis syndrome and other toxicities, such as neutropenia and infections, with venetoclax-based treatment can be dealt with successfully.<\/jats:p>","DOI":"10.1182\/hematology.2020000120","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T22:12:35Z","timestamp":1607119955000},"page":"357-362","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":57,"title":["Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"2020","author":[{"given":"Kirsten","family":"Fischer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othman","family":"Al-Sawaf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020121621170823100_B1","first-page":"1","article-title":"Current perspectives on therapy for chronic lymphocytic leukemia","volume":"40","author":"Awan","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"2020121621170823100_B2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"2020121621170823100_B3","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study [published online ahead of print 28 September 2020]","author":"Kater","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020121621170823100_B4","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"23","key":"2020121621170823100_B5","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"2020121621170823100_B6","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2020121621170823100_B7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"2020121621170823100_B8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"2020121621170823100_B9","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2020121621170823100_B10","first-page":"705","article-title":"Managing tumor lysis syndrome in the era of novel cancer therapies","volume":"8","author":"McBride","year":"2017","journal-title":"J Adv Pract Oncol"},{"issue":"4","key":"2020121621170823100_B11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2020121621170823100_B12","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjh.16345","article-title":"Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia","volume":"188","author":"Gribben","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"2020121621170823100_B13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/17474086.2020.1696185","article-title":"Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia","volume":"13","author":"Iskierka-Ja\u017cd\u017cewska","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2020121621170823100_B14","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(19)30253-4","article-title":"Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations","volume":"7","author":"Tambaro","year":"2020","journal-title":"Lancet Haematol"},{"issue":"21","key":"2020121621170823100_B15","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199805213382104","article-title":"Chlorambucil in indolent chronic lymphocytic leukemia","volume":"338","author":"Dighiero","year":"1998","journal-title":"N Engl J Med"},{"issue":"8","key":"2020121621170823100_B16","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/s41375-020-0747-7","article-title":"Early treatment with FCR versus watch and wait in patients with stage binet a high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial","volume":"34","author":"Herling","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"2020121621170823100_B17","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/leu.2017.246","article-title":"Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the german CLL study group","volume":"31","author":"Hoechstetter","year":"2017","journal-title":"Leukemia"},{"issue":"25","key":"2020121621170823100_B18","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"10129","key":"2020121621170823100_B19","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"2020121621170823100_B20","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am J Hematol"},{"issue":"2","key":"2020121621170823100_B21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"6","key":"2020121621170823100_B22","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2020121621170823100_B23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III Study","volume":"37","author":"Kater","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020121621170823100_B24","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"2020121621170823100_B25","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"30","key":"2020121621170823100_B26","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study [published correction appears in J Clin Oncol. 2020;38(14):1644]","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"2020121621170823100_B27","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2020121621170823100_B28","article-title":"Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): results from the MRD cohort of the phase 2 CAPTIVATE study [abstract]","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"issue":"19","key":"2020121621170823100_B29","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"2020121621170823100_B30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ctrv.2009.11.001","article-title":"An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome","volume":"36","author":"Mughal","year":"2010","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"2020121621170823100_B31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2020121621170823100_B32","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.13403","article-title":"Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology","volume":"169","author":"Jones","year":"2015","journal-title":"Br J Haematol"},{"issue":"18","key":"2020121621170823100_B33","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","article-title":"Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"24","author":"Davids","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"14","key":"2020121621170823100_B34","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2014-07-586610","article-title":"Obinutuzumab (GA101) in relapsed\/refractory chronic lymphocytic leukemia: final data from the phase 1\/2 GAUGUIN study","volume":"124","author":"Cartron","year":"2014","journal-title":"Blood"},{"issue":"14","key":"2020121621170823100_B35","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1158\/1078-0432.CCR-19-0361","article-title":"Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice","volume":"25","author":"Roeker","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2020121621170823100_B36","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1080\/10428194.2020.1768384","article-title":"Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice","volume":"61","author":"Koehler","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"2020121621170823100_B37","article-title":"Venclyxto: Summary or product characteristics","year":"2020"},{"issue":"6","key":"2020121621170823100_B38","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/ejh.13068","article-title":"Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma","volume":"100","author":"Lakshmaiah","year":"2018","journal-title":"Eur J Haematol"},{"key":"2020121621170823100_B39","doi-asserted-by":"crossref","first-page":"haematol.2019.223693","DOI":"10.3324\/haematol.2019.223693","article-title":"Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial","author":"Cramer","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"2020121621170823100_B40","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41375-018-0313-8","article-title":"CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia","volume":"33","author":"von Tresckow","year":"2019","journal-title":"Leukemia"},{"issue":"26","key":"2020121621170823100_B41","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2019-01-896290","article-title":"Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed\/refractory chronic lymphocytic leukemia","volume":"133","author":"Flinn","year":"2019","journal-title":"Blood"},{"issue":"24","key":"2020121621170823100_B42","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1182\/bloodadvances.2018019422","article-title":"Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL","volume":"2","author":"Kater","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"2020121621170823100_B43","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S1470-2045(18)30414-5","article-title":"Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Cramer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2020121621170823100_B44","article-title":"Prevention and management of tumor lysis syndrome in patients with CLL and coexisting conditions treated with venetoclax-obinutuzumab or chlorambucil-obinutuzumab: results from the randomized CLL14 trial [abstract]","volume":"134","author":"Al-Sawaf","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621170823100_B45","article-title":"Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (bloodwise TAP CLARITY study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy [abstract]","volume":"130","author":"Hillmen","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2020121621170823100_B46","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.blre.2018.04.007","article-title":"Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies","volume":"32","author":"Teh","year":"2018","journal-title":"Blood Rev"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/357\/1794961\/hem2020000120c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/357\/1794961\/hem2020000120c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T13:13:35Z","timestamp":1608297215000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/357\/474328\/Preventing-and-monitoring-for-tumor-lysis-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000120","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}